Impact of Anticancer Therapy on the Quality of Life of Sudanese Patients with Breast Cancer at Khartoum Oncology Hospital
November 2022
in “
BMC Women s Health
”
TLDR HER2-targeted or hormonal therapies improve quality of life for Sudanese breast cancer patients.
The study at Khartoum Oncology Hospital evaluated the impact of breast cancer therapies on the quality of life (QOL) of 200 Sudanese patients, revealing that 54.0% experienced poor global health-QOL, with hair loss being the most distressing symptom for 68.6% of patients. Financial difficulties and body image issues were significant concerns. Patients receiving HER2-targeted or hormonal therapies had significantly better QOL and fewer symptoms compared to those on conventional chemotherapy. These therapies were positive predictors of improved QOL, with HER2-targeted therapy increasing the likelihood of good QOL by 10.2 times. The study recommended integrating palliative and supportive care to enhance QOL, acknowledging limitations due to its cross-sectional design and small sample size during the COVID-19 pandemic.